On October 23, AKESO fell 3.28% in Regular Trading, trading at HK$81.15, with turnover of HK$265 million.
The clearest recent catalyst is continued pressure after the company completed a placement of 20 million new shares at HK$97.76 each, raising net proceeds of about HK$1.941 billion. The placement accounts for about 2.13% of enlarged share capital, and recent market attention has focused on dilution and the stock trading below the placing price even after funding uncertainty was partly eased.
Background disclosures show the proceeds are mainly earmarked for R&D, clinical trials, infrastructure and commercialization support. AKESO reported first-half revenue of RMB1.806 billion, up 27.92% year on year, while net loss narrowed to RMB447 million, indicating ongoing heavy investment in core pipelines despite improving operating trends.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments